What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
2 years ago
BD-2 novel, PsA-specific predictive biomarker of clinical arthritis response to SEC. Pts w/ high levels of BD-2 at baseline reach and sustain higher rates of clinical response after tx w/ SEC. Abs 2148 #ACR22 @RheumNow https://t.co/9ZJz2C0Pep https://t.co/5gf2O7B0c5
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr #2193 studies invasive fungal infxn in Autoimm/Rheum dx
- PJP most common (41.5%)
- Mortality highest among fungemia (48.7%) and invasive aspergillosis (38.3%) vs PJP (26.1%)
- Older age, cirrhosis, high dose GC assoc w ↑ mortality
@RheumNow #ACR22
Dr. John Cush RheumNow
2 years ago
Monday: ACR 2022 Daily Recap https://t.co/AKYrkLTPJe
Dr. John Cush RheumNow
2 years ago
We'll be going live with our #ACR22 daily recap at 5pm ET. Find us on Twitter, LinkedIn, Youtube and Facebook. https://t.co/hjAyOOynZM
Strategies to identify patients with suspected inflammatory back pain in the general population is critical for timely and proper diagnosis.
Richard Conway RichardPAConway
2 years ago
Aggarwal @docrota et al. RCT abatacept in IIM - 52 week results. IMACS DOI, FI-2, HAQ-DI, CDASI, TIS, MRC response all numerically better, some statistically significant. There looks like a real effect across all subtypes. @RheumNow #ACR22 Abstr#2237 https://t.co/NdkH8BnSEw https://t.co/l7ufagjniX
Richard Conway RichardPAConway
2 years ago
Kim et al. After first episode VZV in RA or UC treated with JAKi, continued JAKi use does not increase reactivation compared to cessation. @RheumNow #ACR22 Abstr#2220 https://t.co/zx96xgkySU https://t.co/KdniDGCUgI
Md Yuzaiful Md Yusof Yuz6Yusof
2 years ago
#ACR22 Abstr#1656 Promising therapy for #lupus. Cenerimod, S1P1 modulator, controls lymphocyte trafficking out of lymph nodes into blood. Phase 2 dose-ranging RCT didn't meet primary endpoint (adjusted for multiple testing) but mSLEDAI-2K reduced in 4mg dose vs PBO @RheumNow https://t.co/YnENTkqClk
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr #2194- What is my risk of flare after COVID vaccine?
- Up to 3 wks s/p vaccination, no significant assn w/ risk for flare (aIRR 0.89 95% CI 0.8-.098) including after 1st, 2nd, and 3rd dose
- No significant assn by disease, hx of COVID infxn, vaccine type
@RheumNow #ACR22
David Liew drdavidliew
2 years ago
Some RA patients do well.
Some do badly, and get frail even before the age of 65 (6% of pts).
These are the ones that get hit by infections with b/tsDMARDs: see below from MarketScan data. These are the patients we need to watch & protect!
ABST2217 @NamrataRheum #ACR22 @RheumNow https://t.co/DXZjFDnCcn
Richard Conway RichardPAConway
2 years ago
Nakafero et al. Self-controlled case series analysis. No increased risk RMD flare with SARS-CoV-2 vaccination. In fact reduced risk! aIRR 0.89(0.80-0.98). No evidence in any of multiple subanalyses either @RheumNow #ACR22 Abstr#2194 https://t.co/r5pOkdjnR1 https://t.co/YpwMkJ3WVe
Dr. Rachel Tate uptoTate
2 years ago
ACRTIC REWIND finds RA pts w/ sustained clinical remission for at least two years and successfully tapered csDMARDs to half-dose, majority of pts who discontinued csDMARDs remained flare free for 12 months. Abs 2013 #ACR22 @RheumNow https://t.co/HsQz0cJznp https://t.co/QceTXJZiFF
Patricia Harkins DrTrishHarkins
2 years ago
🌱Plants for joints 🌱
👉16wk
👉whole food plant based diet + Phys activity + stress Mx
👉 metabolic syndrome assoc OA hip/knee
💥 substantial ⬇️ pain + stiffness
💥⬆️ physical function
#ACR22 @RheumNow Abst 1644 https://t.co/u6UufpbrcC
Dr. Rachel Tate uptoTate
2 years ago
Thanks for the love #Philly #ACR22 @RheumNow check out our coverage by logging on to https://t.co/xF1bNhZB1C! https://t.co/ncBM0icZ3c
Dr. Antoni Chan synovialjoints
2 years ago
Retrospective cohort study 132 immune checkpoint inhibitor arthritis pts Rx with either TNFi ± MTX or IL6Ri ± MTX have a shorter time to cancer progression but faster arthritis control than patients Rx with MTX alone. Bass A Abs#1669 https://t.co/h0Nq6yd2wf #ACR22 @RheumNow https://t.co/XfXMtdbCPB
Poster Hall